Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile4 entries
2026
Boston Scientific discloses cyberattack disrupting global operations
Issue disclosure
Boston Scientific said on Wednesday that a cyberattack affecting some of its information-technology systems has caused global disruptions and limited access to certain information systems and business applications supporting its operations, including its ability to process and ship customer orders. The company said it does not yet know the full scope and nature of the breach, including operational and financial impacts, and is working with cybersecurity experts to assess and contain the threat and restore affected systems, without a timeline for full restoration.
Company response
Investigation — Boston Scientific
Boston Scientific said it is working with cybersecurity experts to assess and contain the threat and to restore affected functions and systems access, but that it doesn't yet have a timeline for a full restoration.
Source excerpt
Boston Scientific on Wednesday said the hack, which is affecting some of its information-technology systems, has caused global disruptions and limitations of access to certain information systems and business applications that support aspects of its operations, including its ability to process and ship customer orders.
Boston Scientific said it is working with cybersecurity experts to assess and contain the threat and to restore affected functions and systems access, but that it doesn't yet have a timeline for a full restoration.
Boston Scientific has been hit with a cyberattack that is hampering the medical-technology company's ability to fill orders.
2026
FDA classifies Boston Scientific ENROUTE device recall as Class I
Recall announced
The FDA classified a recall of certain Boston Scientific ENROUTE Transcarotid Neuroprotection System and ENROUTE NPS Plus devices as Class I, the most serious type, following reports of arterial sheath tip separation during use. Boston Scientific had sent the initial letter to affected customers on July 9, 2026.
Company response
Recall — Boston Scientific
Boston Scientific sent the initial letter to affected customers on July 9, 2026
Source excerpt
The FDA had classified a recall of certain ENROUTE Transcarotid Neuroprotection System and ENROUTE NPS Plus devices as the most serious type of recall — Class I — following reports of arterial sheath tip separation during use.
Boston Scientific sent the initial letter to affected customers on July 9, 2026
2021
Jury finds Nevro infringed two Boston Scientific patents
Ruling
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
Company response
Denial — Nevro
We disagree with the finding by the jury and plan to appeal
Source excerpt
We disagree with the finding by the jury and plan to appeal
today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier. Two other Boston Scientific lead patents (8,646,172 and 8,650,747) were not infringed. The jury awarded Boston Scientific $20 million.
2010
Improper physician payment enforcement action
The United States Department of Justice fined Boston Scientific $600,000 after the company paid an Army doctor to use its devices and recommend them to other physicians. The matter concerned improper inducement and raised compliance concerns about interactions between medical-device companies and clinicians.